Ambit Biosciences Canada (Toronto, On)
CMDF Investment: $6,082,000 
Private Company
Focus:Cancer  Central Nervous System Disorders  Inflammatory Diseases  
Company Website

Ambit Biosciences is a privately-held biopharmaceutical company that uses groundbreaking technology to discover and develop proprietary small molecule drugs for a variety of clinical indications. Our lead drug candidates include neuroprotectants for treatment of stroke and other CNS disorders and kinase inhibitors for treatment of cancer and inflammatory diseases.

Protiva Biotherapeutics (Burnaby, BC)
CMDF Investment: $5,750,000 
Private Company
Focus:Cancer  Inflammatory Diseases  
Company Website

Protiva is a biotechnology company developing a systemic; non-viral gene-delivery platform. Protiva was spun out of Inex Pharmaceuticals Corporation in 2001; where the technology had been under preclinical development for six years. Protiva is focused on becoming a leader in targeted; gene-delivered protein products that are safe and effective for use in the treatment of cancer and inflammatory diseases.

Trillium Therapeutics (Toronto, ON)
CMDF Investment: $3,270,000 
Private Company
Focus:Infectious Dieases  Inflammatory Diseases  
Company Website

Trillium Therapeutics Inc. (TT) is a private immune therapy research and development company. TTI's focus is to develop therapies that restore balance to the immune system in conditions associated with abnormal and harmful immune responses; such as autoimmune and inflammatory disorders; viral hepatitis and transplant-related organ failure. TTI's business model is to identify therapeutic candidates with promising efficacy profiles in animal models and advance these into clinical testing. It is concentrating its activities on pre-clinical and early clinical development; with the primary objective of demonstrating safety and efficacy in humans. The company will seek development partners for late stage clinical trials.

Viron Therapeutics (London, ON)
CMDF Investment: $7,004,000 
Private Company
Focus:Cardiovascular Diseases & Blood Products  Inflammatory Diseases  
Company Website

Viron is a biopharmaceutical company dedicated to becoming a market leader in the treatment of inflammatory disorders. By harnessing the evolutionary power of viruses that have evolved over millennia to withstand the human body’s protective inflammatory response; the Company is developing powerful protein therapeutics that will block the human body’s inflammatory attack. The Company’s lead compound; VT-111; has recently entered Phase 2 clinical trials for the treatment of vascular inflammation in patients with Acute Coronary Syndromes and is also undergoing late preclinical studies for the treatment of transplant vasculopathy. Viron’s additional pipeline of 5 compounds in preclinical development; combined with a robust discovery program; strongly positions the Company to be a leader in the discovery and commercialization of bio-therapeutics to treat inflammatory based diseases.